Skip to content

Blood Product Supply

Blood Product Supply During COVID-19

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07490314
Enrollment
100
Registered
2026-03-24
Start date
2020-03-01
Completion date
2025-06-25
Last updated
2026-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Brief summary

Data about the links between Coronavirus disease 2019(COVID-19) and the safety of blood products during the pandemic is inadequate. During the COVID-19 pandemic, high volumes of patients receiving blood products due to post-terminal surgical complications depleted stores for the entire hospital, resulting in surgeons unable to acquire emergent blood products. Data from this study can be used to develop a policy on how to handle blood shortage issues during this and future pandemics. Also, this data can be used to determine future policies on use of blood products from COVID-19-positive donors.

Detailed description

* To identify the circumstances associated with observed delays in receiving blood products to use in emergent cases. * Determine the cost/benefit of moribund patients receiving massive transfusion during the COVID-19 pandemic. * Quantify COVID-19 diagnosis and complications in patients arriving with no indication of disease at index admission as relative to in hospital or blood product exposure.

Interventions

OTHERDocument delays and frequencies of inadequate blood products for emergent cases

The COVID-19 pandemic is contributing to delays in blood product acquisition and inadequate blood product supplies for emergent cases in hospitals

Sponsors

Methodist Health System
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

\>\_18 years of age Surgical patients treated at Methodist Dallas Medical Center(MDMC)

Exclusion criteria

\<18 years of age Prisoners Pregnant women

Design outcomes

Primary

MeasureTime frameDescription
Time frame1 yearDates of inadequate or delayed blood products for emergent cases during the timeframe of the COVID-19 pandemic (March 2020 to March 2021) to be compared relative to number of days or cases where no shortages were noted

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORJennifer Burris, Pharm D

Methodist Health System

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 25, 2026